Innate Pharma’s (IPHA) “Buy” Rating Reiterated at HC Wainwright
by Michael Walen · The Markets DailyHC Wainwright reissued their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for Innate Pharma’s FY2030 earnings at $0.42 EPS.
Several other brokerages also recently commented on IPHA. BTIG Research began coverage on Innate Pharma in a report on Thursday, March 12th. They issued a “buy” rating and a $8.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Innate Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.
Innate Pharma Price Performance
NASDAQ IPHA opened at $1.45 on Tuesday. Innate Pharma has a 1-year low of $1.17 and a 1-year high of $2.63. The stock’s 50 day moving average is $1.55 and its two-hundred day moving average is $1.77.
Innate Pharma (NASDAQ:IPHA – Get Free Report) last announced its earnings results on Saturday, February 14th. The company reported ($0.18) EPS for the quarter. The firm had revenue of $2.41 million during the quarter.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC bought a new position in Innate Pharma in the 4th quarter worth approximately $36,000. OLD Mission Capital LLC bought a new position in Innate Pharma in the 4th quarter worth approximately $50,000. Finally, Jane Street Group LLC bought a new position in Innate Pharma in the 4th quarter worth approximately $162,000. Institutional investors own 0.16% of the company’s stock.
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.